-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The study focused on a variant of the PLCG2 gene that makes instructions for producing an enzyme important to brain immune cells called microglia
The scientists used CRISPR gene editing technology to create protective mutations in human stem cells, and then implanted microglia from these stem cells into a humanized rodent model of Alzheimer's disease
"Our study shows for the first time that the P522R variant increases the expression levels of several microglial genes that are decreased in Alzheimer's patients
The variant also increased the number of T cells, or white blood cell immune system cells, in the brain, suggesting that it may increase activation of other important aspects of immune function
The results will help design further studies to understand exactly how microglia and T cells interact to slow the progression of Alzheimer's disease
"Beyond this, the next step may be to identify drugs that can safely increase the enzymatic activity of PLCG2 and further promote protective microglial function," he said
First author Christel Claes wondered if an antibody that stimulates TREM2, like Alector's (AL002) antibody currently in a phase 2 clinical study, could be protective in AD patients similar to the P522R variant
"The PLCG2 P522R mutation is known to increase signaling downstream of TREM2, an AD risk variant, so it would be very interesting to study the effect of TREM2-stimulating antibodies on microglia-T cell crosstalk
Christel Claes, Whitney E.
